SCHEMBL25322708

SCHEMBL25322708

CCn1cc2ccc(C3CCC(C)CN3)cc2n1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.33
SYK P43405 1/20 0.33
SLC5A2 P31639 1/20 0.31
MLLT1 Q03111 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322702 1.00 NOTUM (0.33) NOTUMSYKSLC5A2MLLT1
SCHEMBL25320574 0.90 SLC5A2 (0.37) SLC5A2MLLT1
SCHEMBL25320575 0.90 SLC5A2 (0.37) SLC5A2MLLT1
SCHEMBL25321615 0.88 SLC5A2 (0.36) SLC5A2MLLT1
SCHEMBL25323488 0.85 IRAK4 (0.33)
SCHEMBL24366024 0.84 MAPT (0.43) SYK
SCHEMBL25916910 0.84 MAPT (0.43) SYK
SCHEMBL25321611 0.81 TLR8 (0.34)
SCHEMBL25321613 0.81 TLR8 (0.34)
SCHEMBL25324200 0.81 MAPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN NOTUM 3380/4885SYK 1992/4885SLC5A2 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.